Skip to content
Open access

Real-world 12-month outcomes of risdiplam in spinal muscular atrophy types 2 and 3

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Spinal muscular atrophy is a progressive genetic neuromuscular disorder characterized by degeneration of lower motor neurons and progressive muscle weakness. Risdiplam, an oral survival motor neuron 2 splicing modifier, has demonstrated efficacy in clinical trials; however, real-world data in older and chronically affected patients remain limited. Objective: To evaluate the safety and effectiveness of risdiplam after 12 months of treatment in patients with spinal muscular atrophy types 2 and 3 in a real-world setting. Methods: This retrospective study included patients with genetically confirmed spinal muscular atrophy types 2 and 3 treated with risdiplam and followed for 12 months. All patients were treatment-naïve prior to therapy initiation. Motor function was assessed using the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) or the Hammersmith Functional Motor Scale Expanded (HFMSE), according to functional status. Pulmonary function, including forced vital capacity (FVC) and forced expiratory volume in one second (FEV1), ventilatory support requirements, and bulbar outcomes were evaluated at baseline, 6 months, and 12 months. Results: Sixteen patients were included, with a mean age of 20 years (range 6 to 56) and a mean untreated disease duration of 18 years, reflecting a predominantly chronic and advanced disease population. After 12 months of treatment, 81% of patients showed stabilization or improvement in motor function, while 19% experienced decline. The mean change was 2.1 points on HFMSE and 1.1 points on CHOP-INTEND. Five patients showed improvement greater than 3 points on motor scales. Pulmonary function improved or stabilized in 81% of patients, and the need for ventilatory support remained stable throughout follow-up. All patients maintained oral feeding, with no new indication for gastrostomy. Clinical deterioration was observed in a subset of patients and was associated with factors such as progressive scoliosis and obesity. Adverse events were reported in a minority of patients, mainly gastrointestinal, leading to treatment discontinuation in one case. Conclusion: In this real-world cohort of predominantly chronic patients, risdiplam was associated with sustained functional stabilization and measurable gains in a subset of individuals over 12 months. These findings support the role of treatment even in long-standing disease, while also highlighting that functional outcomes may be influenced by non-neurological factors, which should be considered when interpreting treatment response.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.